Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. Among authors: luo j. bioRxiv [Preprint]. 2024 Mar 29:2024.02.22.581560. doi: 10.1101/2024.02.22.581560. bioRxiv. 2024. PMID: 38464251 Free PMC article. Preprint.
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, Wang Y, Bai L, McEachern D, Luo J, Wang M, Li Q, Matvekas A, Wen B, Sun D, Chinnaiyan AM, Wang S. Chen Z, et al. Among authors: luo j. J Med Chem. 2024 Apr 11;67(7):5351-5372. doi: 10.1021/acs.jmedchem.3c01789. Epub 2024 Mar 26. J Med Chem. 2024. PMID: 38530938
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J, Chen Z, Qiao Y, Ching-Yi Tien J, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. Luo J, et al. bioRxiv [Preprint]. 2024 Mar 30:2024.03.29.587346. doi: 10.1101/2024.03.29.587346. bioRxiv. 2024. PMID: 38586029 Free PMC article. Preprint.
Comprehensive proteogenomic characterization of rare kidney tumors.
Li GX, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, Petralia F, Cho H, Hosseini N, Leprevost FDV, Calinawan A, Li Y, Anand S, Dagar A, Geffen Y, Kumar-Sinha C, Chugh S, Le A, Ponce S, Guo S, Zhang C, Schnaubelt M, Al Deen NN, Chen F, Caravan W, Houston A, Hopkins A, Newton CJ, Wang X, Polasky DA, Haynes S, Yu F, Jing X, Chen S, Robles AI, Mesri M, Thiagarajan M, An E, Getz GA, Linehan WM, Hostetter G, Jewell SD, Chan DW, Wang P, Omenn GS, Mehra R, Ricketts CJ, Ding L, Chinnaiyan AM, Cieslik MP, Dhanasekaran SM, Zhang H, Nesvizhskii AI; Clinical Proteomic Tumor Analysis Consortium. Li GX, et al. Among authors: luo j. Cell Rep Med. 2024 May 21;5(5):101547. doi: 10.1016/j.xcrm.2024.101547. Epub 2024 May 3. Cell Rep Med. 2024. PMID: 38703764
21,370 results
You have reached the last available page of results. Please see the User Guide for more information.